Definium Therapeutics, Inc. (DFTX) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Definium Therapeutics, Inc. (DFTX) closed at USD 34.24 on 2026-10-14, a change of +166 % over the past year, with a market capitalization of USD 4.6B.

Definium Therapeutics, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Definium Therapeutics, Inc. key figures

Previous close

USD 34.24 (2026-10-14)

1-year change

+166 %

Market cap

USD 4.6B

Enterprise value

USD 3.56B

P/E ratio (trailing)

-10.02

P/E ratio (forward)

-17.66

EPS (trailing)

-3.42

EPS (forward)

-1.94

PEG ratio

n/a

Price to book

5.01

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

4.80

Employees

105

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Definium Therapeutics, Inc.

Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company's lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc. and changed its name to Definium Therapeutics, Inc. in January 2026. Definium Therapeutics, Inc. is headquartered in New York, New York.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Definium Therapeutics, Inc. and compare it with other stocks.